In this regard, novel small molecules targeting neutrophilic inflammation, such as chemokine (CXC) receptor 2 (CXCR2) antagonists have been analyzed in the noneosinophilic asthma context, showing how these antagonists reduce neutrophils, but do not improve clinical outcomes in studies to date (47). Here, CXCR2 is linked to asthma.